PRV UL4 is a promotor of NLRP3 inflammasome Activation. by Xiaohua Zhang (350570)

Subjects:

Bar chart of state-wise annual temperature shift. by MD. Nahid Hassan Nishan (22264861)

Subjects:

Demographic characteristics of the participants. by MD. Nahid Hassan Nishan (22264861)

Subjects:

Data for Fig 6D. by Xiaohua Zhang (350570)

Subjects:

PRV UL4 also promotes AIM2-inflammasome activation. by Xiaohua Zhang (350570)

Subjects:

Data for Fig 5D. by Xiaohua Zhang (350570)

Subjects:

Data for Figs 8A–8H, 9A–9K, 10A–10I. by Xiaohua Zhang (350570)

Subjects:

Statistically significant linear increase in use of psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics, gabapentinoids during the observed time period. by Jelena Filimonovic (22305307)

Subjects:

Joinpoint regression trends in crude hospitalization and mortality rates of HPV-associated cancers in Mexico (2011–2019). by Juan Carlos Orengo (21546581)

Subjects:

Restricted cubic spline plots showing the association between changes in PAL and risk of CVD. by Haiwei Li (282229)

Subjects:

Multivariate logistic regression analysis on the risk factors associated with prolonged APTT. by Huan Wang (109286)

Subjects:

Sociodemographic, occupational, and clinical risk factors associated with low workability and results of Logistic regression analysis among diabetic workers. by Sarah A. Bolbol (21702891)

Subjects:

Initial participants by wave*. by Yeo Ju Sohn (18536198)

Subjects:

General characteristics of research participants. by Yeo Ju Sohn (18536198)

Subjects:

Patient demographics. by Katrine Carlsen (5477300)

Subjects:

Changes in alpha diversity in the weeks before anti-TNF-a treatment. by Katrine Carlsen (5477300)

Subjects:

Alpha diversity measures across all 727 samples. by Katrine Carlsen (5477300)

Subjects:

Summary statistics for analysis of single genera clades. by Katrine Carlsen (5477300)

Subjects:

Abundance of the top 20 most abundant genera in one patient (Patient 1), across the weeks running up to treatment. by Katrine Carlsen (5477300)

Subjects:

Development of alpha diversity across weeks towards a new TNF treatment for each IBD disease subtype. by Katrine Carlsen (5477300)

Subjects: